(1) For paragraph 136F(1)(c) of the Act, the pharmaceutical product must be labelled or marked in a way that:
(a) clearly identifies the product as being exported from Australia under the PPI compulsory licence; and
(b) distinguishes the product from:
(i) the same pharmaceutical product as sold in Australia; and
(ii) the same pharmaceutical product as exported other than under the licence.
(2) For subregulation (1), the labelling or marking must:
(a) be applied to:
(i) the immediate package containing the pharmaceutical product; and
(ii) any other package containing that package (whether or not other packages are involved); and
(b) remain clear and legible at all times while the product is being exported.